Drug delivery has grown in leaps and bounds in recent decades, including growth in administration methods, therapeutic formulation, and delivery systems. David Bunka, chief technical officer, Aptamer Group, joins Meg Rivers, senior editor, for a deep dive into Optimers (optimized aptamers). Bunka discusses some of the key differences between Optimer drug conjugates and antibody-drug conjugates (ADCs), such as their properties, how they are created, and potential immune responses. He also shares how Optimers can target malignant cells without prior knowledge of specific biomarkers, the scalability capabilities of Optimers due to their chemistry/being synthetically manufactured, and what long-term safety could look like.

SPONSOR: JRS Pharma